Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 7/20 | 0.93 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.52 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.52 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.52 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.52 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.52 |
| ▸ | KDM5A | P29375 | 3/20 | 0.49 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | KMO | O15229 | 1/20 | 0.46 |
| ▸ | CCNA2 | P20248 | 4/20 | 0.46 |
| ▸ | CDK2 | P24941 | 4/20 | 0.46 |
| ▸ | CCNA1 | P78396 | 4/20 | 0.46 |
| ▸ | TACR3 | P29371 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16564029 | 0.98 | HCAR2 (0.90) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL6761699 | 0.96 | HCAR2 (1.00) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3517472 | 0.93 | HCAR2 (1.00) | HCAR2KDM5ADAOCCNA2CDK2 | |
| SCHEMBL27620587 | 0.78 | HCAR2 (0.59) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL4127272 | 0.77 | HCAR2 (0.57) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL25139438 | 0.76 | HCAR2 (0.71) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3929157 | 0.76 | HCAR2 (0.71) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL16564121 | 0.76 | HCAR2 (0.56) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL3387649 | 0.73 | HCAR2 (0.61) | HCAR2HDAC3HDAC4HDAC1HDAC7 | |
| SCHEMBL18711801 | 0.72 | HCAR2 (0.65) | HCAR2HDAC3HDAC4HDAC1HDAC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967204-B2 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC (US) | 2005-11-22 | — | — | US | disclosed |
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER INC | 2005-03-31 | — | — | US | disclosed |
| CN-1575191-A | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | PFIZER PROD INC (US) | 2005-02-02 | — | — | CN | disclosed |
| WO-2004096811-A1 | PDE9 INHIBITORS FOR TREATING TYPE 2 DIABETES, METABOKIC SYNDROME, AND CARDIOVASCULAR DISEASE | PFIZER PRODUCTS INC. (US) | 2004-11-11 | — | — | WO | disclosed |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PFIZER INC. | 2004-11-04 | — | — | US | disclosed |
| EP-1444009-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | Pfizer Products Inc. (US) | 2004-08-11 | — | — | EP | disclosed |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | FRYBURG DAVID A (US) | 2004-02-05 | — | — | US | disclosed |
| WO-2003037432-A1 | TREATMENT OF INSULIN RESISTANCE SYNDROME AND TYPE 2 DIABETES WITH PDE9 INHIBITORS | PFIZER PRODUCTS INC. (US) | 2003-05-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050070557-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR2 1033/4885HDAC3 1506/4885HDAC4 976/4885 |
| US-20040220186-A1 | PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease | PDE9A, PDE2A, PDE12 | HCAR2 1162/4885HDAC3 1008/4885HDAC4 1271/4885 |
| US-20040023989-A1 | Treatment of insulin resistance syndrome and type 2 diabetes with PDE9 inhibitors | GPR119, PDE2A, PDE9A | HCAR2 1033/4885HDAC3 1506/4885HDAC4 976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.